It also increased the antitumor activity of the pyrimidine antimetabolite gemcitabine (GEM) against HCC by activation of the NKG2D and DAP10/Akt pathways that lead to activation of NK cells. This evidence concerns the gene KLRK1 and hepatocellular carcinoma.